Skip to main content
LCTX
NYSE Life Sciences

Broadwood's Bradsher Buys 1M LCTX Shares for $770,700 Open-Market

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.853
Mkt Cap
$207.423M
52W Low
$0.77
52W High
$1.985
52W Position info
11% above low
Off High info
57% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

LCTX is trading near its 52-week low of $0.77 (11% above the low).

Summary

Broadwood Partners bought 1,000,000 Lineage shares at $0.7707 for about $770,700, the largest of four open-market insider purchases filed this week and the first disclosure of this transaction.


Key Events · Ownership and Investor Activity · LCTX

  • Broadwood Buys 1M Shares Open-Market

    Broadwood Partners, L.P. acquired 1,000,000 common shares at $0.7707 on 2026-11-17, a total of about $770,700, per the Form 4.

  • Largest Buy in This Week's Cluster

    At roughly $770,700 this is about 20x the other insider purchases filed 2026-11-16 to 2026-11-19 (CEO $37,098, CFO $17,100, two directors $20,000 and $26,100), making it the anchor of a four-insider accumulation.

  • Holdings and Warrant Overhang

    Post-transaction beneficial ownership is 50,560,992 shares plus 7,894,737 common warrants exercisable at $0.91, so the buyer is an existing 10% owner adding to a large position rather than a new entrant.

  • Context: Post-Acquisition, Funded Balance Sheet

    Follows the 2026-11-12 8-K on the ~$4.7M NeuroAirmid/HUNT1 acquisition and a 10-Q showing $45.2M in cash and marketable securities against a $23.8M nine-month operating loss.


Analysis · LCTX · Life Sciences

The company's largest holder and a board member put real cash into the stock — 1,000,000 shares at $0.7707, roughly $770,700 — rather than exercising options or receiving a grant. That is about 20x the size of the other insider purchases filed this week (CEO $37,098, CFO $17,100, director $20,000, director $26,100), so it is the anchor of a genuine accumulation cluster: four insiders buying on the open market in the last several days. The purchase lands a week after the 8-K disclosing the ~$4.7M NeuroAirmid/HUNT1 acquisition and a 10-Q showing $45.2M in cash against a $23.8M nine-month operating loss, so insiders are buying into a story where the balance sheet is funded but the burn is real. Caveat on conviction: Broadwood is a 10% owner, and the filing shows 50,560,992 shares plus 7,894,737 warrants at a $0.91 strike, so this is an existing large holder adding to a position, not a new entrant.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LCTX was trading at $0.85 on NYSE in the Life Sciences sector, with a market capitalization of approximately $207.4M. The 52-week trading range was $0.77 to $1.99. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LCTX - Latest Insights

LCTX
Nov 12, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.990
Real-time Price: $0.8533 info
Change: -$0.1367 (-14%) info
Market Cap: $207.423M info